Novo Nordisk Forges Multi-Billion Dollar Pact to Advance Oral Therapeutics

Novo Nordisk partners with Vivtex to develop oral biologics for obesity and diabetes, a strategic move following clinical setbacks and pricing pressures on its injectable GLP-1 drugs.

Danish pharmaceutical giant Novo Nordisk has moved to secure a promising new technology platform, entering a licensing agreement with Vivtex Corporation in late February 2026. The collaboration is focused on developing novel oral treatments for obesity and diabetes, representing a strategic shift as the company navigates recent clinical and commercial challenges.

Strategic Shift Follows Clinical and Pricing Pressures

The partnership arrives during a complex period for Novo Nordisk. Earlier in the week, the company disclosed that its Phase III REDEFINE 4 trial for the obesity treatment candidate CagriSema failed to meet its primary endpoint. The study did not demonstrate non-inferiority in weight reduction compared to a competing therapy from Eli Lilly.

Compounding this development are planned price reductions for Novo Nordisk's blockbuster GLP-1 drugs, Wegovy and Ozempic, in the United States, scheduled for early 2027. These injectable therapies are among the corporation's most significant revenue drivers. The Vivtex deal is viewed as a direct response to intensifying market competition, aiming to diversify the company's technological base and expand its pipeline beyond established injection-based products.

Unlocking the Potential of Oral Biologics

At the heart of the agreement is Vivtex's proprietary platform, which is designed to enhance the gastrointestinal absorption of biological drugs. Such therapeutics are typically administered via injection; a successful oral formulation would significantly simplify patient treatment regimens. Following the development phase, Novo Nordisk will assume global marketing responsibilities for any resulting products.

The total potential value of the arrangement could reach $2.1 billion. This sum comprises upfront payments, research funding, and potential milestone payments. Additionally, the deal includes provisions for tiered royalty payments on future sales.

This multi-billion dollar investment underscores Novo Nordisk's commitment to pioneering next-generation drug delivery systems. Whether these oral biologic candidates can successfully reach the market and fulfill their potential will become clearer in the coming years.